Nationwide Statistical Analysis of Lymphoid Malignancies in Korea
2
조회
0
다운로드
17
인용
0
참고문헌
키워드
초록
Purpose Regional differences in the incidence of lymphoid malignancies have been reported worldwide, but there has been no large-scale epidemiologic analysis in Korea. The aim of this study was to provide a nationwide population-based statistical analysis of Korean patients with lymphoid malignancies. Materials and Methods The Korea Central Cancer Registry analyzed the incidence and survival of patients with lymphoid malignancies from the Korean National Cancer Incidence Database. Diseases were grouped by clinically relevant categories based on the 2008 World Health Organization classification. Results Overall 65,948 lymphoid diseases were identified between 1999 and 2012. The incidence of most subtypes increased with age, except for precursor cell neoplasms. Male predominance (male:female ratio=1.28:1) was observed. In 2012, annual age-standardized incidence rates per 100,000 persons of Hodgkin’s lymphoma, mature B-cell neoplasm, mature T/natural killer (NK)–cell neoplasm, and precursor cell neoplasm were 0.46, 6.60, 0.95, and 1.50, respectively, and they increased yearly from 1999. Composite Hodgkin’s and non-Hodgkin’s lymphomas were extremely rare. Survival improvement estimated using 5-year relative survival rate was observed in patients with Hodgkin’s lymphoma (71.1%- 83.0%), diffuse large B-cell lymphoma (49.5%-61.5%), plasma cell neoplasms (20.2%- 36.9%), and lymphoblastic lymphoma/leukemia (41.5%-56.3%) between 1993 and 2012. However, survival rates of T/NK-cell lymphoma (excluding cutaneous T-cell lymphoma) ranged from 40.5%-43.5% during the study period. Survival rates decreased with age in most subtypes. Conclusion This report presented the subtype-specific statistical analysis of lymphoid malignancies in the Korean population, showing increasing incidences and survival rates in most subtypes.
Abstract
Purpose Regional differences in the incidence of lymphoid malignancies have been reported worldwide, but there has been no large-scale epidemiologic analysis in Korea. The aim of this study was to provide a nationwide population-based statistical analysis of Korean patients with lymphoid malignancies. Materials and Methods The Korea Central Cancer Registry analyzed the incidence and survival of patients with lymphoid malignancies from the Korean National Cancer Incidence Database. Diseases were grouped by clinically relevant categories based on the 2008 World Health Organization classification. Results Overall 65,948 lymphoid diseases were identified between 1999 and 2012. The incidence of most subtypes increased with age, except for precursor cell neoplasms. Male predominance (male:female ratio=1.28:1) was observed. In 2012, annual age-standardized incidence rates per 100,000 persons of Hodgkin’s lymphoma, mature B-cell neoplasm, mature T/natural killer (NK)–cell neoplasm, and precursor cell neoplasm were 0.46, 6.60, 0.95, and 1.50, respectively, and they increased yearly from 1999. Composite Hodgkin’s and non-Hodgkin’s lymphomas were extremely rare. Survival improvement estimated using 5-year relative survival rate was observed in patients with Hodgkin’s lymphoma (71.1%- 83.0%), diffuse large B-cell lymphoma (49.5%-61.5%), plasma cell neoplasms (20.2%- 36.9%), and lymphoblastic lymphoma/leukemia (41.5%-56.3%) between 1993 and 2012. However, survival rates of T/NK-cell lymphoma (excluding cutaneous T-cell lymphoma) ranged from 40.5%-43.5% during the study period. Survival rates decreased with age in most subtypes. Conclusion This report presented the subtype-specific statistical analysis of lymphoid malignancies in the Korean population, showing increasing incidences and survival rates in most subtypes.
참고문헌 (30)
- Torre LA, "Global cancer statistics, 2012", CA Cancer J Clin, 65, pp.87~108 (2015)[DOI]
- Swerdlow SH, "WHO classification of tumours of haematopoietic and lymphoid tissues. 4th ed." (2008), IARC Press
- Muller AM, "Epidemiology of non-Hodgkin's lymphoma (NHL): trends, geographic distribution, and etiology", Ann Hematol, 84, pp.1~12 (2005)
- Rudiger T, "Peripheral T-cell lymphoma (excluding anaplastic large-cell lymphoma): results from the Non-Hodgkin's Lymphoma Classification Project", Ann Oncol, 13, pp.140~149 (2002)[DOI]
- Ohshima K, "The World Health Organization classification of malignant lymphoma: incidence and clinical prognosis in HTLV-1-endemic area of Fukuoka", Pathol Int, 52, pp.1~12 (2002)[DOI]
- Harris NL, "A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group", Blood, 84, pp.1361~1392 (1994)
- Bennett JM, "Proposals for the classification of chronic (mature) B and T lymphoid leukaemias. French-American-British (FAB) Cooperative Group", J Clin Pathol., 42, pp.567~584 (1989)[DOI]
- Bennett JM, "Proposals for the classification of the acute leukaemias. French-American-British (FAB) co-operative group", Br J Haematol., 33, pp.451~458 (1976)[DOI]
- Percy C, "International classification of diseases for oncology (ICD-O). 3rd ed." (2000)
- Marcos-Gragera R, "Survival of European patients diagnosed with lymphoid neoplasms in 2000-2002: results of the HAEMACARE project", Haematologica, 96, pp.720~728 (2011)[DOI]
- Sant M, "Incidence of hematologic malignancies in Europe by morphologic subtype: results of the HAEMACARE project", Blood, 116, pp.3724~3734 (2010)[DOI]
- Hyeon Jin Park, "Statistics of hematologic malignancies in Korea: incidence, prevalence and survival rates from 1999 to 2008", Blood Research, 47(1), pp.28~38 (2012), 대한혈액학회
- Segi M, "Cancer mortality for selected sites in 24 countrues (1950-1957)" (1960)
- [URL]
- Ederer F, "The relative survival rate: a statistical methodology", Natl Cancer Inst Monogr, 6, pp.101~121 (1961)
- Dickman PW, "Regression models for relative survival", Stat Med, 23, pp.51~64 (2004)[DOI]
- Instructions to IBM 650 programmers in processing survival computations. Methodological note No. 10. End results evaluation section, "Ederer F", National Cancer Institute, ~ (1959)
- Bassig BA, "Subtype-specific incidence rates of lymphoid malignancies in Hong Kong compared to the United States, 2001-2010", Cancer Epidemiol, 42, pp.15~23 (2016)[DOI]
- Chihara D, "Differences in incidence and trends of haematological malignancies in Japan and the United States", Br J Haematol, 164, pp.536~545 (2014)[DOI]
- 정규원, "Cancer Statistics in Korea: Incidence, Mortality, Survival, and Prevalence in 2012", Cancer Research and Treatment, 47(2), pp.127~141 (2015), 대한암학회[DOI]
- Won YW, "Clinical features and outcomes of Hodgkin's lymphoma in Korea: Consortium for Improving Survival of Lymphoma (CISL)", Ann Hematol, 91, pp.223~233 (2012)[DOI]
- Jarrett RF, "Impact of tumor Epstein-Barr virus status on presenting features and outcome in age-defined subgroups of patients with classic Hodgkin lymphoma: a population-based study", Blood, 106, pp.2444~2451 (2005)[DOI]
- Engert A, "Hodgkin's lymphoma in elderly patients: a comprehensive retrospective analysis from the German Hodgkin's Study Group", J Clin Oncol, 23, pp.5052~5060 (2005)[DOI]
- Flowers CR, "Disparities in the early adoption of chemoimmunotherapy for diffuse large B-cell lymphoma in the United States", Cancer Epidemiol Biomarkers Prev, 21, pp.1520~1530 (2012)[DOI]
- Bruce CJ, "Rituxan anniversary: 10 years of progress", Oncol Bus Rev., pp.18~19 (2007)
- Kim SJ, "Phase II trial of concurrent radiation and weekly cisplatin followed by VIPD chemotherapy in newly diagnosed, stage IE to IIE, nasal, extranodal NK", T-Cell Lymphoma: Consortium for Improving Survival of Lymphoma study, 2009, pp.27, 6027~6032
- Kwong YL, "SMILE for natural killer", T-cell lymphoma: analysis of safety and efficacy from the Asia Lymphoma Study Group, 2012, pp.120, 2973~2980
- Moorman AV, "A population-based cytogenetic study of adults with acute lymphoblastic leukemia", Blood, 115, pp.206~214 (2010)[DOI]
- Veal GJ, "Clinical pharmacology in the adolescent oncology patient", J Clin Oncol, 28, pp.4790~4799 (2010)[DOI]
- Bleyer A, "Adolescents and young adults with cancer: the scope of the problem and criticality of clinical trials", Cancer, 107(7 Suppl), pp.1645~1655 (2006)[DOI]